Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 44Prostatic Neoplasms, Castration-Resistant 6Neoplasm Metastasis 4Metastatic Castration-resistant Prostate Cancer 4Prostate Carcinoma Metastatic to the Bone 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Hormone Refractory Prostate Cancer 2Carcinoma, Renal Cell 2Bone Metastatic Castration-resistant Prostate Cancer 2Prostate Cancer Metastatic to Bone 1Prostate Adenocarcinoma 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Lymphatic Metastasis 1Fractures, Bone 1Castration-resistant Prostate Cancer 1Castrate-Resistant Prostate Cancer 1Bony Metastases From Castrate Refractory Prostate Cancer 1Bone Neoplasms 1Bone Metastases 1Advanced Prostate Cancer 1

Interventions

Docetaxel 35pembrolizumab 32Nivolumab 27enzalutamide 20Prednisone 20Sunitinib 16Cyclophosphamide 16aldesleukin 14Zoledronic Acid 13Interleukin-2 13Gemcitabine 13Bevacizumab 13Specimen Handling 12Ipilimumab 12Radiosurgery 11Everolimus 11Androgen Antagonists 11Abiraterone Acetate 11fludarabine 10Sorafenib 10Radiotherapy 10Paclitaxel 10Magnetic Resonance Spectroscopy 10pazopanib 9abiraterone 9Doxorubicin 8Carboplatin 8Biopsy 8avelumab 7temsirolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasm Metastasis × radium Ra 223 dichloride × Genitourinary × Clear all
NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Icahn School of Medicine at Mount Sinai

Phase 2 Completed
40 enrolled 18 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00337155 2023-11-02

BAY88-8223, Dose Finding Study in Patients With HRPC

Bayer

Phase 2 Completed
122 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00459654 2014-06-25

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

Bayer

Phase 2 Completed
64 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00748046 2014-06-25

Alpharadinâ„¢ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

Bayer

Phase 1 Completed
10 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡